Voluntary announcement proposed share repurchase on the market
Filed with HKEX · · 2 pages · English
Summary by 6ix AI
GenFleet Therapeutics (Shanghai), Inc. has announced a proposed share repurchase on the market. The board has resolved to exercise a mandate to repurchase H shares, with a maximum amount not exceeding a specified limit. The share repurchase aims to enhance shareholder value and reflects the board's confidence in the company's long-term prospects. Shareholders are advised that the repurchase will depend on market conditions and will be at the board's discretion.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Genfleet Therapeutics (Shanghai), Inc. on 6ix
Later from Genfleet Therapeutics (Shanghai)
- VOLUNTARY ANNOUNCEMENT Favorable Phase II Efficacy Data of GFH375 (Oral KRAS G12D Inhibitor) Monotherapy in Pretreated NSCLC Presented in Oral Session at 2026 World Conference on Lung Cancer (WCLC)
- 2026 Interim Report
- VOLUNTARY ANNOUNCEMENT Announcement on the Progress of Share Repurchase
- Announcement pursuant to rule 13.10 of the listing rules
- VOLUNTARY ANNOUNCEMENT Disclosure Arrangements for Clinical Data from Studies of GFH375 and GFH276
Follow Genfleet Therapeutics (Shanghai) into a list and get an email when it puts out news.
Follow Genfleet Therapeutics (Shanghai)